Homocysteine and Cognitive Function

 

 Buy Article Permissions and Reprints

ABSTRACT

The prevention and treatment of age-related cognitive impairment and dementia is one of the greatest and most elusive challenges of our time. The prevalence of dementia increases exponentially with age, as does the prevalence of those with micronutrient deficiency. Several studies have shown that elevated homocysteine is correlated with cognitive decline and with cerebral atrophy and that it predicts the subsequent development of dementia in cognitively intact middle-aged and elderly individuals. If elevated homocysteine promotes cognitive dysfunction, then lowering homocysteine by means of B-vitamin supplementation may protect cognitive function by arresting or slowing the disease process.

REFERENCES

• 1 Katzman R, Kawas C. The epidemiology of dementia and Alzheimer disease. In: Terry RD, Katzman R, Bick KL Alzheimer Disease New York; Rave Press 1994: 105-122
  Google Scholar
• 2 Smith A D. Homocysteine, B vitamins and cognitive deficit in the elderly.  Am J Clin Nutr. 2002;  75 785-786
  PubMedGoogle Scholar
• 3 Beiser A, Au R, DeCarli C et al.. Higher levels of plasma homocysteine are associated with subsequent lower brain volume and poorer performance on tests of attention and concentration: the Framingham offspring study. The 8th International Conference on Alzheimer's Disease and Related Disorders Stockholm, Sweden; July 20-25, 2002
  Google Scholar
• 4 Seshadri S, Beiser A, Selhub J et al.. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.  N Engl J Med. 2002;  346 476-483
  CrossrefPubMedGoogle Scholar
• 5 Selhub J, Bagley L C, Miller J, Rosenberg I H. B vitamins, homocyseine, and neurocognitive function in the elderly.  Am J Clin Nutr. 2000;  71 614S-620S
  PubMedGoogle Scholar
• 6 Yoo J H, Chung C S, Kang S S. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis.  Stroke. 1998;  29 2478-2483
  PubMedGoogle Scholar
• 7 Bostom A G, Rosenberg I H, Silbershatz H et al.. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study.  Ann Intern Med. 1999;  131 352-355
  PubMedGoogle Scholar
• 8 Brattstrom L E, Hardevo J E, Hultverg B L. Moderate homocysteinemia-a possible risk factor for arteriosclerotic cerebrovascular disease.  Stroke. 1984;  15 1012-1016
  PubMedGoogle Scholar
• 9 Boushey C J, Beresford S AA, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.  JAMA. 1995;  274 1049-1057
  Google Scholar
• 10 Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy.  Lancet. 1999;  353 1586-1587
  CrossrefPubMedGoogle Scholar
• 11 Hogervorst E, Ribeiro H M, Molyneux A, Budge M, Smith A D. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease.  Arch Neurol. 2002;  59 787-793
  CrossrefPubMedGoogle Scholar
• 12 Clarke R, Smith A D, Jobst K A, Refsum H, Sutton L, Ueland P M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease.  Arch Neurol. 1998;  55 1449-1455
  CrossrefPubMedGoogle Scholar
• 13 Moller J, Nielsen G M, Tvedegaard K C, Andersen N T, Jorgensen P E. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia.  Scand J Clin Lab Invest. 2000;  60 491-499
  PubMedGoogle Scholar
• 14 Alfthan G, Pekkanen J, Jauhiainen M et al.. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.  Atherosclerosis. 1994;  106 9-19
  CrossrefPubMedGoogle Scholar
• 15 Fallon U B, Elwood P, Ben-Shlomo Y, Ubbink J B, Greenwood R, Smith G D. Homocysteine and ischaemic stroke in men: the Caerphilly study.  J Epidemiol Community Health. 2001;  55 91-96
  PubMedGoogle Scholar
• 16 Verhoef P, Hennekens C H, Malinow M R, Kok F J, Willett W C, Stampfer M J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.  Stroke. 1994;  25 1924-1930
  CrossrefPubMedGoogle Scholar
• 17 Bots M L, Launer L J, Lindemans J et al.. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study.  Arch Intern Med. 1999;  159 38-44
  CrossrefPubMedGoogle Scholar
• 18 Perry I J, Refsum H, Morris R W, Ebrahim S B, Ueland P M, Shaper A G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.  Lancet. 1995;  346 1395-1398
  CrossrefPubMedGoogle Scholar
• 19 Ridker P M, Manson J E, Buring J E, Shih J, Matias M, Hennekens C H. Homocysteine and risk of cardiovascular disease among postmenopausal women.  JAMA. 1999;  281 1817-1821
  CrossrefPubMedGoogle Scholar
• 20 Casas J, Bautista L, Smeeth L, Sharma P, Hingorani A. Homocysteine and stroke: evidence on a causal link from mendelian randomization.  Lancet. 2005;  365 224-232
  PubMedGoogle Scholar
• 21 Joosten E, Lesaffre E, Riezler R et al.. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?.  J Gerontol A Biol Sci Med Sci. 1997;  52 M76-M79
  PubMedGoogle Scholar
• 22 McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type.  Int J Geriatr Psychiatry. 1998;  13 235-239
  CrossrefPubMedGoogle Scholar
• 23 Miller J W, Green R, Mungas D M, Reed B R, Jagust W J. Homocysteine, vitamin B6, and vascular disease in AD patients.  Neurology. 2002;  58 1471-1475
  PubMedGoogle Scholar
• 24 Luchsinger J A, Tang M X, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease.  Neurology. 2004;  62 1972-1976
  PubMedGoogle Scholar
• 25 Ravaglia G, Forti P, Maioli F et al.. Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment.  Mech Ageing Dev. 2000;  121 251-261
  PubMedGoogle Scholar
• 26 Storey S G, Suryadevara V, Aronow W S, Ahn C. Association of plasma homocysteine in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease.  J Gerontol A Biol Sci Med Sci. 2003;  58 M1135-M1136
  PubMedGoogle Scholar
• 27 Religa D, Styczynska M, Peplonska B et al.. Homocysteine, apolipoprotein E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment.  Dement Geriatr Cogn Disord. 2003;  16 64-70
  CrossrefPubMedGoogle Scholar
• 28 Lehmann M, Gottfries C G, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker.  Dement Geriatr Cogn Disord. 1999;  10 12-20
  CrossrefPubMedGoogle Scholar
• 29 Leblhuber F, Walli J, Artner-Dworzak E et al.. Hyperhomocysteinemia in dementia.  J Neural Transm. 2000;  107 1469-1474
  CrossrefPubMedGoogle Scholar
• 30 Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration relates to the severity but not to the duration of Alzheimer's disease.  Int J Geriatr Psychiatry. 2004;  19 666-672
  PubMedGoogle Scholar
• 31 de la Torre J C. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging.  Gerontology. 1997;  43 26-43
  PubMedGoogle Scholar
• 32 Kalaria R N, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia.  Alzheimer Dis Assoc Disord. 1999;  13 S115-S123
  PubMedGoogle Scholar
• 33 Moody D M, Brown W R, Challa V R, Ghazi-Birry H S, Reboussin D M. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease.  Ann N Y Acad Sci. 1997;  826 103-116
  PubMedGoogle Scholar
• 34 Morris J H. Vascular dementia. In: Esiri MM, Morris JH The Neuropathology of Dementia Cambridge; Cambridge University Press 1997: 137-173
  Google Scholar
• 35 O'Brien M D. Vascular dementia is underdiagnosed.  Arch Neurol. 1988;  45 797-798
  PubMedGoogle Scholar
• 36 Nagy Z, Esiri M M, Jobst K A et al.. The effects of additional pathology on the cognitive deficit in Alzheimer disease.  J Neuropathol Exp Neurol. 1997;  56 165-170
  PubMedGoogle Scholar
• 37 Pollak R D, Pollak A, Idelson M, Bejarano-Achache I, Doron D, Blumenfeld A. The C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and vascular dementia.  J Am Geriatr Soc. 2000;  48 664-668
  PubMedGoogle Scholar
• 38 Fassbender K, Mielke O, Bertsch T, Nafe B, Fröschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy.  Lancet. 1999;  353 1586-1587
  CrossrefPubMedGoogle Scholar
• 39 Brookmeyer R, Curriero F C. Survival curve estimation with partial non-random exposure information.  Stat Med. 2002;  21 2671-2683
  CrossrefPubMedGoogle Scholar
• 40 Morris M S, Jacques P F, Rosenberg I H, Selhub J. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey.  Am J Clin Nutr. 2001;  73 927-933
  PubMedGoogle Scholar
• 41 Riggs K M, Spiro A r, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study.  Am J Clin Nutr. 1996;  63 306-314
  PubMedGoogle Scholar
• 42 Bell I R, Edman J S, Selhub J et al.. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people.  Acta Psychiatr Scand. 1992;  86 386-390
  PubMedGoogle Scholar
• 43 Budge M, Johnston C, Hogervorst E et al.. Plasma total homocysteine and cognitive performance in a volunteer elderly population.  Ann N Y Acad Sci. 2000;  903 407-410
  PubMedGoogle Scholar
• 44 Duthie S J, Whalley L J, Collins A R, Leaper S, Berger K, Deary I J. Homocysteine, B vitamin status, and cognitive function in the elderly.  Am J Clin Nutr. 2002;  75 908-913
  PubMedGoogle Scholar
• 45 Miller J W, Green R, Ramos M I et al.. Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging.  Am J Clin Nutr. 2003;  78 441-447
  PubMedGoogle Scholar
• 46 Kalmijn S, Launer L J, Lindemans J, Bots M L, Hofman A, Breteler M M. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study.  Am J Epidemiol. 1999;  150 283-289
  PubMedGoogle Scholar
• 47 Teunissen C E, Blom A H, Van Boxtel M P et al.. Homocysteine: a marker for cognitive performance? A longitudinal follow-up study.  J Nutr Health Aging. 2003;  7 153-159
  PubMedGoogle Scholar
• 48 McCaddon A, Hudson P, Davies G, Hughes A, Williams J H, Wilkinson C. Homocysteine and cognitive decline in healthy elderly.  Dement Geriatr Cogn Disord. 2001;  12 309-313
  CrossrefPubMedGoogle Scholar
• 49 Kado D, Karlamangla A, Huang M et al.. Homocysteine versus the vitamins folate, B6 and B12 as predictors of cognitive function and cognitive decline in older high functioning adults: MacArthur studies of successful aging.  Am J Med. 2005;  , In press
  PubMedGoogle Scholar
• 50 Clarke R, Joachim C, Esiri M et al.. Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia.  Ann N Y Acad Sci. 2000;  903 497-500
  PubMedGoogle Scholar
• 51 Sachdev P. Homocysteine, cerebrovascular disease and brain atrophy.  J Neurol Sci. 2004;  226 25-29
  CrossrefPubMedGoogle Scholar
• 52 Scott T M, Tucker K L, Bhadelia A et al.. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders.  Am J Geriatr Psychiatry. 2004;  12 631-638
  PubMedGoogle Scholar
• 53 Vermeer S E, van Dijk E J, Koudstaal P J et al.. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study.  Ann Neurol. 2002;  51 285-289
  CrossrefPubMedGoogle Scholar
• 54 den Heijer T, Vermeer S E, Clarke R et al.. Homocysteine and brain atrophy on MRI of non-demented elderly.  Brain. 2003;  126 170-175
  PubMedGoogle Scholar
• 55 Prins N D, Den Heijer T, Hofman A et al.. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study.  Neurology. 2002;  59 1375-1380
  PubMedGoogle Scholar
• 56 Dufouil C, Alperovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people.  Ann Neurol. 2003;  53 214-221
  CrossrefPubMedGoogle Scholar
• 57 Troen A M, Lutgens E, Smith D E, Rosenberg I H, Selhub J. The atherogenic effect of excess methionine intake.  Proc Natl Acad Sci USA. 2003;  100 15089-15094
  CrossrefPubMedGoogle Scholar

Aron TroenPh.D. 

Nutrition and Neurocognition Laboratory and Vitamin Metabolism and Aging Laboratory

The Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts